Literature DB >> 29149237

Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States.

Cherise Wong1, Stephen J Gange1, Richard D Moore2, Amy C Justice3, Kate Buchacz4, Alison G Abraham1, Peter F Rebeiro5, John R Koethe5, Jeffrey N Martin6, Michael A Horberg7, Cynthia M Boyd2, Mari M Kitahata8, Heidi M Crane8, Kelly A Gebo2, M John Gill9, Michael J Silverberg10, Frank J Palella11, Pragna Patel4, Hasina Samji12, Jennifer Thorne2, Charles S Rabkin13, Angel Mayor14, Keri N Althoff1.   

Abstract

Background: Age-associated conditions are increasingly common among persons living with human immunodeficiency virus (HIV) (PLWH). A longitudinal investigation of their accrual is needed given their implications on clinical care complexity. We examined trends in the co-occurrence of age-associated conditions among PLWH receiving clinical care, and differences in their prevalence by demographic subgroup.
Methods: This cohort study was nested within the North American AIDS Cohort Collaboration on Research and Design. Participants from HIV outpatient clinics were antiretroviral therapy-exposed PLWH receiving clinical care (ie, ≥1 CD4 count) in the United States during 2000-2009. Multimorbidity was irreversible, defined as having ≥2: hypertension, diabetes mellitus, chronic kidney disease, hypercholesterolemia, end-stage liver disease, or non-AIDS-related cancer. Adjusted prevalence ratios (aPR) and 95% confidence intervals (CIs) comparing demographic subgroups were obtained by Poisson regression with robust error variance, using generalized estimating equations for repeated measures.
Results: Among 22969 adults, 79% were male, 36% were black, and the median baseline age was 40 years (interquartile range, 34-46 years). Between 2000 and 2009, multimorbidity prevalence increased from 8.2% to 22.4% (Ptrend < .001). Adjusting for age, this trend was still significant (P < .001). There was no difference by sex, but blacks were less likely than whites to have multimorbidity (aPR, 0.87; 95% CI, .77-.99). Multimorbidity was the highest among heterosexuals, relative to men who have sex with men (aPR, 1.16; 95% CI, 1.01-1.34). Hypertension and hypercholesterolemia most commonly co-occurred. Conclusions: Multimorbidity prevalence has increased among PLWH. Comorbidity prevention and multisubspecialty management of increasingly complex healthcare needs will be vital to ensuring that they receive needed care.

Entities:  

Mesh:

Year:  2018        PMID: 29149237      PMCID: PMC5889007          DOI: 10.1093/cid/cix998

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 2.  New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

Authors:  Christine A Hughes; Linda Robinson; Alice Tseng; Rodger D MacArthur
Journal:  Expert Opin Pharmacother       Date:  2009-10       Impact factor: 3.889

3.  Differences between infectious diseases-certified physicians and general medicine-certified physicians in the level of comfort with providing primary care to patients.

Authors:  Shawn L Fultz; Joseph L Goulet; Sharon Weissman; David Rimland; David Leaf; Cynthia Gibert; Maria C Rodriguez-Barradas; Amy C Justice
Journal:  Clin Infect Dis       Date:  2005-07-22       Impact factor: 9.079

4.  Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.

Authors:  Amanda Mocroft; Peter Reiss; Jacek Gasiorowski; Bruno Ledergerber; Justyna Kowalska; Antonio Chiesi; Jose Gatell; Aza Rakhmanova; Margaret Johnson; Ole Kirk; Jens Lundgren
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

5.  HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users.

Authors:  Megan L Salter; Bryan Lau; Vivian F Go; Shruti H Mehta; Gregory D Kirk
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

6.  Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.

Authors:  Barbara Hasse; Bruno Ledergerber; Hansjakob Furrer; Manuel Battegay; Bernhard Hirschel; Matthias Cavassini; Barbara Bertisch; Enos Bernasconi; Rainer Weber
Journal:  Clin Infect Dis       Date:  2011-10-13       Impact factor: 9.079

7.  Weight change after antiretroviral therapy and mortality.

Authors:  Bianca Yuh; Janet Tate; Adeel A Butt; Kristina Crothers; Matthew Freiberg; David Leaf; Mary Logeais; David Rimland; Maria C Rodriguez-Barradas; Christopher Ruser; Amy C Justice
Journal:  Clin Infect Dis       Date:  2015-03-11       Impact factor: 9.079

8.  Retention among North American HIV-infected persons in clinical care, 2000-2008.

Authors:  Peter Rebeiro; Keri N Althoff; Kate Buchacz; John Gill; Michael Horberg; Hartmut Krentz; Richard Moore; Timothy R Sterling; John T Brooks; Kelly A Gebo; Robert Hogg; Marina Klein; Jeffrey Martin; Michael Mugavero; Sean Rourke; Michael J Silverberg; Jennifer Thorne; Stephen J Gange
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

9.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

10.  Non-Communicable Disease Preventive Screening by HIV Care Model.

Authors:  Corinne M Rhodes; Yuchiao Chang; Susan Regan; Virginia A Triant
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

View more
  53 in total

1.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

2.  Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis.

Authors:  Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash
Journal:  AIDS Patient Care STDS       Date:  2019-03       Impact factor: 5.078

3.  Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996-2016.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; David A Wohl; Amy L Durr; Oksana Zakharova; Claire E Farel; Joseph J Eron
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 4.  Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.

Authors:  Samson Okello; Abdallah Amir; Gerald S Bloomfield; Katie Kentoffio; Henry M Lugobe; Zahra Reynolds; Itai M Magodoro; Crystal M North; Emmy Okello; Robert Peck; Mark J Siedner
Journal:  Prog Cardiovasc Dis       Date:  2020-02-05       Impact factor: 8.194

5.  Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.

Authors:  Herieth Ismael Wilson; Herry Mapesi
Journal:  Pan Afr Med J       Date:  2020-11-17

6.  Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Joseph J Eron; Stephen R Cole; David van Duin; David A Wohl; Brenna C Hogan; Keri N Althoff; Kelly A Gebo; Richard D Moore; Michael J Silverberg; Michael A Horberg; M John Gill; W Christopher Mathews; Marina B Klein; Jonathan A Colasanti; Timothy R Sterling; Angel M Mayor; Peter F Rebeiro; Kate Buchacz; Jun Li; Ni Gusti Ayu Nanditha; Jennifer E Thorne; Ank Nijhawan; Stephen A Berry
Journal:  J Infect Dis       Date:  2020-12-26       Impact factor: 5.226

7.  Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals.

Authors:  Janet P Tate; Jonathan A C Sterne; Amy C Justice
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

8.  Aging and HIV infection: focus on cardiovascular disease risk.

Authors:  Judith A Aberg
Journal:  Top Antivir Med       Date:  2020-01

9.  Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.

Authors:  Ighovwerha Ofotokun; Lauren F Collins; Kehmia Titanji; Antonina Foster; Caitlin A Moran; Anandi N Sheth; Cecile D Lahiri; Jeffrey L Lennox; Laura Ward; Kirk A Easley; M Neale Weitzmann
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

10.  Comorbidity patterns among people living with HIV: a hierarchical clustering approach through integrated electronic health records data in South Carolina.

Authors:  Xueying Yang; Jiajia Zhang; Shujie Chen; Sharon Weissman; Bankole Olatosi; Xiaoming Li
Journal:  AIDS Care       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.